In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva, with a price target of $20.00. The company’s shares closed yesterday at $6.24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Madrigal Pharmaceuticals, and Travere Therapeutics. According to TipRanks, Nash has an average return of 18.9% and a 48.23% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inventiva with a $19.20 average price target, implying a 207.69% upside from current levels. In a report released on September 29, Guggenheim also reiterated a Buy rating on the stock with a $13.00 price target.
The company has a one-year high of $6.55 and a one-year low of $1.60. Currently, Inventiva has an average volume of 52.2K.
Read More on IVA:
Disclaimer & DisclosureReport an Issue
- 3 Best Stocks to Buy Now, 10/02/2025, According to Top Analysts
- Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress
- Inventiva management to meet with Piper Sandler
- Inventiva Appoints Andrew Obenshain as CEO to Drive U.S. Market Expansion
- Inventiva SA Reports Progress and Challenges in 2025
/AI%20(artificial%20intelligence)/Image%20of%20server%20racks%20in%20modern%20server%20room%20data%20center%20by%20Sashkin%20via%20Shutterstock.jpg)
